Company Filing History:
2 out of 68 
1 out of 60 
Years Active: 2018-2019
Title: Madlaina Breuleux: Innovator in Biomarker Research
Introduction
Madlaina Breuleux is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of biomarker research, particularly in relation to drug response in cancer treatment. With a total of 2 patents, her work is paving the way for advancements in personalized medicine.
Latest Patents
Breuleux's latest patents focus on the use of BUBR1 as a biomarker for predicting drug response to furazanobenzimidazoles. The first patent details the application of BUBR1 in predicting the response to a compound, specifically targeting resistance to diseases such as cancer. The second patent reiterates this innovative approach, emphasizing the potential of BUBR1 in enhancing treatment efficacy.
Career Highlights
Throughout her career, Madlaina Breuleux has worked with notable organizations, including Basilea Pharmaceutica AG and Ruprecht-Karls-Universität Heidelberg. Her experience in these institutions has allowed her to collaborate with leading experts in the field, further enriching her research and contributions.
Collaborations
Some of her notable coworkers include Heidi Alexandra Lane and Felix Bachmann. Their collaborative efforts have played a crucial role in advancing the research initiatives that Breuleux is involved in.
Conclusion
Madlaina Breuleux's innovative work in biomarker research is making a significant impact in the field of cancer treatment. Her patents and collaborations highlight her dedication to improving drug response prediction, ultimately benefiting patients worldwide.